GetTopicDetailResponse(id=2bcc61959a, topicName=dostarlimab, introduction=dostarlimab, content=null, image=null, comments=3, allHits=1127, url=https://h5.medsci.cn/topic?id=6195, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=102898, tagList=[TagDto(tagId=102898, tagName=dostarlimab)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1972908, encodeId=7d2f19e2908c1, content=<a href='/topic/show?id=2bcc61959a' target=_blank style='color:#2F92EE;'>#dostarlimab#</a>, objectTitle=ASCO GI 2020：dostarlimab在錯(cuò)配修復(fù)缺陷（dMMR）實(shí)體瘤取得積極療效數(shù)據(jù), objectType=article, longId=205841, objectId=b4b220584147, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4b220584147, replyNumber=0, likeNumber=97, createdTime=2021-06-30, rootId=0, userName=12498568m50暫無(wú)昵稱, userId=1e452500029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4b220584147, moduleTitle=ASCO GI 2020：dostarlimab在錯(cuò)配修復(fù)缺陷（dMMR）實(shí)體瘤取得積極療效數(shù)據(jù), moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=b4b220584147)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1972909, encodeId=438019e290939, content=<a href='/topic/show?id=2bcc61959a' target=_blank style='color:#2F92EE;'>#dostarlimab#</a>, objectTitle=復(fù)發(fā)或晚期錯(cuò)配修復(fù)缺陷的子宮內(nèi)膜癌：Dostarlimab的臨床活性和安全性, objectType=article, longId=206100, objectId=b08320610035, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b08320610035, replyNumber=0, likeNumber=110, createdTime=2021-07-16, rootId=0, userName=12498568m50暫無(wú)昵稱, userId=1e452500029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b08320610035, moduleTitle=復(fù)發(fā)或晚期錯(cuò)配修復(fù)缺陷的子宮內(nèi)膜癌：Dostarlimab的臨床活性和安全性, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=b08320610035)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1972907, encodeId=646719e29073a, content=<a href='/topic/show?id=2bcc61959a' target=_blank style='color:#2F92EE;'>#dostarlimab#</a>, objectTitle=全新分析支持PD-1抑制劑dostarlimab在子宮內(nèi)膜癌中的應(yīng)用, objectType=article, longId=193027, objectId=5ab819302e68, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ab819302e68, replyNumber=0, likeNumber=93, createdTime=2020-09-02, rootId=0, userName=12498568m50暫無(wú)昵稱, userId=1e452500029, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ab819302e68, moduleTitle=全新分析支持PD-1抑制劑dostarlimab在子宮內(nèi)膜癌中的應(yīng)用, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=5ab819302e68)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
